SIMPLEX QUANTUM, Completes US Patent Registration of Artificial Intelligence Technology Designed

By AIT News Desk On Oct 12, 2022

University of Tokyo Hospital collaborated on development of the technology designed to reduce the burden on medical staff performing heart failure staging

SIMPLEX QUANTUM, has completed registration in the United States of a patent for technology designed to use artificial intelligence (AI) to stage heart failure.

Latest Aithority Insights : NVIDIA Raises the Standard of Low Code DevOps with the NVIDIA AI Enterprise 2.1

“Our new technology is designed to automate heart failure staging”

Patent US 11,412,978 B2 describes the technology as an information processing system to reduce labor of medical staff in determining heart failure stage.

The system references data from hundreds of thousands of electrocardiograms (ECGs) interpreted by clinicians to determine heart failure stage. The SIMPLEX QUANTUM processor executes a software program to determine heart failure stage using deep learning methodology.

In the current diagnostic process, a clinician detects heart failure by obtaining a patient’s electrocardiogram and clinical information including heart rate and respiratory rate. Determining the stage of heart failure is an additional, often time-consuming step. “Our new technology is designed to automate heart failure staging,” says SIMPLEX QUANTUM CEO Ryu Saito.

US patent registration follows registration in Japan and filing in countries worldwide. SIMPLEX QUANTUM technology has not yet received US Food and Drug Administration (FDA) clearance for marketing in the US. With its pre-submission application to the FDA, the company has initiated the regulatory pathway to market of its technology as a medical device in the US.

Future of AI-driven Customer Relationship: Microsoft’s Viva Sales and the Future of AI-driven Customer Relationship and Experience Management

[To share your insights with us, please write to sghosh@martechseries.com]